ESPNSource: Seahawks signing RB Mixon with rookie Price on IRESPN DeportesAitana Bonmatí explica "nueva realidad" en Barcelona tras lesiónInquirerHighlights: Day 33 of Sara Duterte impeachment trial | Oct. 5, 2026Daily MaverickJUDICIAL APPOINTMENTS: JSC fills Supreme Court of Appeal vacancies amid pressure to reformZDF heuteEntdecken Sie das ZDF-NachrichtenstudioRFICambodge: la diaspora appelée à voter pour un Parlement en exil symbolique pour promouvoir la démocratieسكاي نيوز عربيةالكشف عن جوانب من خفايا سحب قاذفات B-1 الأميركية من بريطانياThe Hollywood ReporterHarry Potter Goes Grunge With a Surprisingly Wearable New Lifestyle CollectionNOSBritse auteur en politicus Jeffrey Archer op 86-jarige leeftijd overledenThe Jerusalem Post'Twisted Torah': Israeli leaders criticize Rabbi Lando anti-Zionist viewsالشرقالتحالف يعلن تدمير منصة صواريخ في صنعاء ومخزن يضم 20 صاروخاً بصعدةMexico News DailyTijuana and Mexicali businesses at center of latest US sanctions targeting alleged Sinaloa Cartel network
The Daily Newsstand · Free, Always
Monday, October 5, 2026

Medicine Nobel goes to US-German trio for pioneering light-based control of cells

Translate

American psychiatrist and neurologist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel won the Nobel Prize in Medicine for discoveries that allow researchers to control nerve cells using light.

05 Oct 2026 10:13PM

STOCKHOLM: The Nobel medicine prize was awarded Monday (Oct 5) to American psychiatrist and neurologist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel for their pioneering work in the neuroscience field of optogenetics.

Optogenetics involves controlling nerve signals with light, and helps researchers understand how specific cell types contribute to behaviours like learning, fear, addiction and movement.

The trio were honoured "for their discovery of a molecular switch for nerve cells", the Nobel Assembly said.

Using light, researchers are now able to switch individual neural circuits on or off in a brain.

They have been able to reveal neural circuits governing specific memories, feelings, and behaviours relevant for neurological and psychiatric disorders.

In clinical medicine, the method has been used on humans on a very limited basis, particularly to treat a specific form of blindness, and may one day lead to treatments for disorders such as Parkinson's disease and epilepsy.

"Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of," Per Svenningsson, chair of the Nobel committee, said in a statement.

The jury said the field had "fundamentally altered our understanding of the brain".

The secretary general of the assembly, Thomas Perlmann, told reporters he was able to reach the three laureates by phone to break the news.

"I first called Deisseroth, he was very tired when he answered. He was definitely asleep, but he woke up," he said.

"All three said the same thing, that they thought it was absolutely wonderful to receive the prize with the other two."

'Seen it coming'

"This is one of those Nobel prizes that we've all seen coming for quite a while now," Simon Schultz, professor of neurotechnology in the department of bioengineering at Imperial College London, said in comments sent to AFP.

"Being able to manipulate cells with a combination of light and genetics has been transformational across the biological sciences," he said.

Karl Deisseroth a co-winner of the 2026 Nobel Prize in Physiology or Medicine, poses for a portrait at Deisseroth’s CNC Lab at Stanford University School of Medicine in Palo Alto, California, US Aug 10, 2021. (Photo: Jim Gensheimer/Reuters)

One of the key areas for future development is its use in humans, said Konstantin Nikolic, visiting professor in electrical and electronic engineering at Imperial College London.

While there were initial ethical and safety concerns about introducing genes encoding non-human, typically microbial, proteins into human cells, "the field has progressed considerably, and optogenetic approaches have already entered early-stage clinical trials," he said.

Deisseroth, 54, is a professor at Stanford University in the United States, while Hegemann, 71, is a neuroscience professor at Humboldt University of Berlin.

Nagel, 73, is a biophysics professor at the University of Wurzburg.

In a comment posted on X, German Chancellor Friedrich Merz said: "This award shows that German research is top-notch. International collaboration in science remains crucial."

Illumination

In the early 2000s, Hegemann and Nagel were examining why a single-celled alga was able to swim toward a light source.

They discovered an algal protein with unique properties, called channelrhodopsin, found on the surface of the cell.

When illuminated by blue light, a channel opens through the protein.

The press conference at the Nobel Forum at Karolinska Institute in Stockholm, Sweden, Oct 5, 2026. (Photo: Pontus Lundahl/ Reuters)

Charged ions then flow into the cell, creating an electrical impulse. They found that any cell they put the protein in became light sensitive.

Deisseroth then introduced the gene for channelrhodopsin into nerve cells from rats.

By illuminating the cells with blue light, he was able to trigger a nerve signal.

He published his breakthrough in 2005, and two years later, made the light-controlled switch for nerve cells work in the brains of living mice.

In 2021, Deisseroth and Hegemann won the Lasker Prize for their work, often considered a precursor to the Nobel.

The Nobel prize for physics will be announced on Tuesday, followed by the chemistry prize on Wednesday and the literature prize on Thursday.

The peace prize will be announced on Friday, and the economics prize will round off the Nobel season on October 12.

This year's laureates will receive their prizes - a diploma, a gold medal and US$1.2-million to share - on Dec 10, the anniversary of the death in 1896 of the prize's founder, scientist Alfred Nobel.

View the original on Channel News Asia →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.